Molecular studies have revealed that acute lymphoblastic leukemia (ALL), mainly diagnosed in children and adolescents, is comprised of distinct sub-groups of the disease, involving a range of intracellular pathways, some of which are associated with poorer outcomes. Over the last 15 years, researchers have been able to utilise these biological differences to develop targeted and personalised risk-adapted treatment strategies, which has dramatically improved ALL survival rates.
Study 10 draws on this progress by providing all patients with reliable MRD (minimal residual disease) based risk stratification at three different time points and response-oriented treatment. This approach aims to give long-term impact whilst optimising patient care.
Disease stage: Newly diagnosed
Patient age range: Children and adolescents < 18 years of age
- National: ANZCHOG
- International: University Medical Centre Schleswig-Holstein, Germany